Active Ingredient History
Bococizumab is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders." Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Cardiovascular Diseases (Phase 3)
Dyslipidemias (Phase 3)
Healthy Volunteers (Phase 1)
Homozygous Familial Hypercholesterolemia (Phase 3)
Hypercholesterolemia (Phase 2)
Hyperlipidemias (Phase 3)
Lipid Metabolism Disorders (Phase 1)
Metabolic Diseases (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue